{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Renal+Pelvis+Cancer+AJCC+v8",
    "query": {
      "condition": "Stage II Renal Pelvis Cancer AJCC v8"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:02:25.457Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04953104",
      "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Bladder Urothelial Carcinoma",
        "Recurrent Renal Pelvis Urothelial Carcinoma",
        "Recurrent Ureter Urothelial Carcinoma",
        "Recurrent Urethral Urothelial Carcinoma",
        "Recurrent Urothelial Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Unresectable Bladder Urothelial Carcinoma",
        "Unresectable Renal Pelvis Urothelial Carcinoma",
        "Unresectable Ureter Urothelial Carcinoma",
        "Unresectable Urethral Urothelial Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Diagnostic Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Relatlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-21",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04953104"
    },
    {
      "nct_id": "NCT03513952",
      "title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Bladder Urothelial Carcinoma",
        "Advanced Ureter Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Bladder Urothelial Carcinoma",
        "Recurrent Renal Pelvis Urothelial Carcinoma",
        "Recurrent Ureter Urothelial Carcinoma",
        "Recurrent Urethral Urothelial Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Unresectable Bladder Urothelial Carcinoma",
        "Unresectable Renal Pelvis Urothelial Carcinoma",
        "Unresectable Ureter Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Glycosylated Recombinant Human Interleukin-7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography and Computed Tomography Scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2019-06-05",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 9,
      "location_summary": "Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03513952"
    },
    {
      "nct_id": "NCT02812420",
      "title": "Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hydronephrosis",
        "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant",
        "Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant",
        "Renal Pelvis Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage II Renal Pelvis Cancer AJCC v7",
        "Stage II Ureter Cancer AJCC v7",
        "Stage II Urethral Cancer AJCC v7",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Renal Pelvis Cancer AJCC v7",
        "Stage III Ureter Cancer AJCC v7",
        "Stage III Urethral Cancer AJCC v7",
        "Stage IV Renal Pelvis Cancer AJCC v7",
        "Stage IV Ureter Cancer AJCC v7",
        "Stage IV Urethral Cancer AJCC v7",
        "Ureter Urothelial Carcinoma",
        "Urethral Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2017-03-07",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02812420"
    },
    {
      "nct_id": "NCT05756569",
      "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Squamous Cell Carcinoma",
        "Locally Advanced Bladder Carcinoma",
        "Malignant Renal Pelvis Neoplasm",
        "Malignant Ureter Neoplasm",
        "Malignant Urethral Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Unresectable Bladder Carcinoma",
        "Urachal Adenocarcinoma",
        "Bladder Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-09-26",
      "completion_date": "2027-12-16",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05756569"
    },
    {
      "nct_id": "NCT03617913",
      "title": "Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
        "Stage II Bladder Cancer AJCC v8",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage II Ureter Cancer AJCC v8",
        "Stage II Urethral Cancer AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Urethral Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2018-09-19",
      "completion_date": "2020-07-27",
      "has_results": true,
      "last_update_posted_date": "2023-01-06",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03617913"
    },
    {
      "nct_id": "NCT06661720",
      "title": "Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Renal Cell Carcinoma (RCC)",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tivozanib",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1040,
      "start_date": "2025-03-14",
      "completion_date": "2037-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 410,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 327 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06661720"
    },
    {
      "nct_id": "NCT04871529",
      "title": "Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
        "Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma",
        "Stage II Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-08-10",
      "completion_date": "2024-06-26",
      "has_results": true,
      "last_update_posted_date": "2024-12-30",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 92,
      "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Highlands Ranch",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04871529"
    },
    {
      "nct_id": "NCT04398368",
      "title": "Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage 0a Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage 0a Renal Pelvis Cancer AJCC v8",
        "Stage 0a Ureter Cancer AJCC v8",
        "Stage 0is Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage 0is Renal Pelvis Cancer AJCC v8",
        "Stage 0is Ureter Cancer AJCC v8",
        "Stage I Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage I Renal Pelvis Cancer AJCC v8",
        "Stage I Ureter Cancer AJCC v8",
        "Stage II Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage II Ureter Cancer AJCC v8",
        "Stage III Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage IV Renal Pelvis and Ureter Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2020-06-05",
      "completion_date": "2023-02-02",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Winston-Salem, North Carolina + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04398368"
    },
    {
      "nct_id": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Locally Advanced Bladder Carcinoma",
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Renal Pelvis Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Melanoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v6",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2021-09-23",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04940299"
    },
    {
      "nct_id": "NCT00749892",
      "title": "Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Bladder Urothelial Carcinoma",
        "Recurrent Renal Pelvis Urothelial Carcinoma",
        "Recurrent Ureter Urothelial Carcinoma",
        "Recurrent Urethral Urothelial Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage 0a Renal Pelvis Cancer AJCC v8",
        "Stage 0a Ureter Cancer AJCC v8",
        "Stage 0a Urethral Cancer AJCC v8",
        "Stage 0is Bladder Cancer AJCC v8",
        "Stage 0is Renal Pelvis Cancer AJCC v8",
        "Stage 0is Ureter Cancer AJCC v8",
        "Stage 0is Urethral Cancer AJCC v8",
        "Stage II Bladder Cancer AJCC v8",
        "Stage II Renal Pelvis Cancer AJCC v8",
        "Stage II Ureter Cancer AJCC v8",
        "Stage II Urethral Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2008-06-10",
      "completion_date": "2019-11-26",
      "has_results": true,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-05-22T04:02:25.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749892"
    }
  ]
}